Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2018

Open Access 01-12-2018 | Correction

Correction to: Anti-tumor effects of Atractylenolide I on bladder cancer cells

Authors: Rui Yu, Bi-xia Yu, Jun-feng Chen, Xiu-yi Lv, Ze-jun Yan, Yue Cheng, Qi Ma

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2018

Login to get access

Excerpt

In the publication of this article [1], there is an error in Fig. 4b. The Cyto c western blot image in Fig. 4b is misrepresented. This has now been included in this correction. The authors declare that the correction does not change the results or conclusions of this paper. …
Literature
1.
Metadata
Title
Correction to: Anti-tumor effects of Atractylenolide I on bladder cancer cells
Authors
Rui Yu
Bi-xia Yu
Jun-feng Chen
Xiu-yi Lv
Ze-jun Yan
Yue Cheng
Qi Ma
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2018
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-018-0913-1

Other articles of this Issue 1/2018

Journal of Experimental & Clinical Cancer Research 1/2018 Go to the issue

Research

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

Review

Relevance of 3d culture systems to study osteosarcoma environment

Review

Fate of Antibody-Drug Conjugates in Cancer Cells

Research

Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling

Review

Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy

Research

Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits